GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADMA Biologics Inc (NAS:ADMA) » Definitions » Net Margin %

ADMA (ADMA Biologics) Net Margin % : 29.96% (As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is ADMA Biologics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. ADMA Biologics's Net Income for the three months ended in Sep. 2024 was $35.9 Mil. ADMA Biologics's Revenue for the three months ended in Sep. 2024 was $119.8 Mil. Therefore, ADMA Biologics's net margin for the quarter that ended in Sep. 2024 was 29.96%.

The historical rank and industry rank for ADMA Biologics's Net Margin % or its related term are showing as below:

ADMA' s Net Margin % Range Over the Past 10 Years
Min: -387.07   Med: -181.23   Max: 17.8
Current: 17.8


ADMA's Net Margin % is ranked better than
88.65% of 1013 companies
in the Biotechnology industry
Industry Median: -140.3 vs ADMA: 17.80

ADMA Biologics Net Margin % Historical Data

The historical data trend for ADMA Biologics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADMA Biologics Net Margin % Chart

ADMA Biologics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -164.50 -179.41 -88.52 -42.77 -10.94

ADMA Biologics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.81 -23.88 21.75 29.91 29.96

Competitive Comparison of ADMA Biologics's Net Margin %

For the Biotechnology subindustry, ADMA Biologics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ADMA Biologics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ADMA Biologics's Net Margin % distribution charts can be found below:

* The bar in red indicates where ADMA Biologics's Net Margin % falls into.



ADMA Biologics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

ADMA Biologics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-28.239/258.215
=-10.94 %

ADMA Biologics's Net Margin for the quarter that ended in Sep. 2024 is calculated as

Net Margin=Net Income (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=35.909/119.839
=29.96 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ADMA Biologics  (NAS:ADMA) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


ADMA Biologics Net Margin % Related Terms

Thank you for viewing the detailed overview of ADMA Biologics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


ADMA Biologics Business Description

Traded in Other Exchanges
N/A
Address
465 State Route 17, Ramsey, NJ, USA, 07446
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
Executives
Adam S Grossman director, officer: President and CEO 65 COMMERCE WAY, HACKENSACK NJ 07601
Lawrence P. Guiheen director 65 COMMERCE WAY, HACKENSACK NJ 07601
Jerrold B Grossman director 65 COMMERCE WAY, HACKENSACK NJ 07601
Young Kwon director C/O MOMENTA PHARMACEUTICALS INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Steve Elms director 888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106
Alison Cecily Finger director C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Bryant Fong director 2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123
Brian Lenz officer: EVP, CFO 65 COMMERCE WAY, HACKENSACK NJ 07601
Martha J Demski director 7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
James Mond officer: CSO/CMO 65 COMMERCE WAY, HACKENSACK NJ 07601
Biotest Divestiture Trust 10 percent owner C/O ERIC ROSENBACH, TRUSTEE, 402 NORFOLK STREET, CAMBRIDGE MA 02139
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Eric I Richman director C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854

ADMA Biologics Headlines

From GuruFocus